NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free RAIN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.21▼$1.2150-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32VolumeN/AAverage Volume550,818 shsMarket Capitalization$44.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Rain Oncology alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Rain Oncology Stock (NASDAQ:RAIN)As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… RAIN Stock News HeadlinesMarch 28, 2024 | uk.sports.yahoo.comHere's how green rain works in Stardew ValleyMarch 27, 2024 | msn.comPhillies Opening Day delayed due to rainMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 26, 2024 | msn.comVery strong wind & widespread rain: ForecastMarch 25, 2024 | msn.comEaster weather: Rain could put dampener on four-day weekend, Met Office warnsMarch 25, 2024 | msn.comI-Team: Woman accused of stealing $30K from Brush principal’s cancer fund goes before judgeMarch 24, 2024 | msn.comThousands of N.S. residents lose power as heavy winds, rain batter provinceMarch 24, 2024 | msn.comPHOTOS: 6-year-old cancer patient’s Make-a-Wish granted on Kings Dominion’s opening dayMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! March 23, 2024 | msn.comNew Yorkers wish Kate Middleton well in wake of cancer diagnosis — and hope she’s left in peaceMarch 23, 2024 | msn.comPHOTOS: 6-year-old cancer patient’s Make-a-Wish is being granted, kicked off on Kings Dominion’s opening dayMarch 23, 2024 | msn.comHeavy rain, strong winds didn't stop Hampton Roads residents from heading outsideMarch 23, 2024 | msn.comCancer survivors round the world rally around Kate Middleton: ‘Sisters for life’March 23, 2024 | msn.comCoastal storm brings heavy rain, gusty winds to NY, NJMarch 23, 2024 | msn.comGirl rescued after 16 hours under mud as heavy rain leaves seven dead in BrazilMarch 23, 2024 | msn.comKate’s cancer diagnosis was the reason Prince William skipped godfather King Constantine of Greece’s memorial serviceMarch 23, 2024 | msn.comPrincess Kate says she is in early stages of cancerMarch 23, 2024 | msn.comPrincess of Wales announces she has cancerMarch 22, 2024 | msn.comDenver weather: Weekend storm to change sunny skies to rain and snowMarch 22, 2024 | msn.comKate Middleton reveals she is being treated for cancerMarch 22, 2024 | msn.comNYC storm set to dump up to 3 inches of rain with Saturday ‘washout’ expectedMarch 22, 2024 | msn.comPacific storm to bring rain, wind to San Diego County this weekendMarch 21, 2024 | msn.comPhiladelphia Phillies 5K takes on new meaning for breast cancer survivorMarch 21, 2024 | msn.comPernice Brothers Share Anthemic Track “The Purple Rain” from the Upcoming Album ‘Who Will You Believe’March 21, 2024 | msn.comWeather Impact Day: Heavy rain for Friday eveningMarch 20, 2024 | msn.comRichard Simmons apologizes after ‘dying’ message, reveals skin cancer diagnosisMarch 19, 2024 | msn.comMichigan woman advocates for colorectal cancer funding in DCSee More Headlines Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RAIN CUSIPN/A CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-82.96% Return on Assets-68.31% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book0.39Miscellaneous Outstanding Shares36,380,000Free Float30,047,000Market Cap$44.02 million OptionableOptionable Beta0.27 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Avanish Vellanki M.B.A. (Age 49)Co-Founder, CEO & Chairman Comp: $959.75kDr. Robert C. Doebele M.D. (Age 53)Ph.D., Co-Founder, Chairman of Scientific Advisory Board, President & CSO and Chief Medical Officer Comp: $700.56kMs. Josephine Bruce (Age 45)Principal Financial & Accounting officer Ms. Theresa O'Connell M.S.Director of Corporate Development & OperationsMr. Erik Atkisson (Age 52)General Counsel & Chief Compliance Officer Ms. Charmi TurnerVice President of People & CultureMs. Vijaya Tirunagaru Ph.D.Senior VP & Head of ResearchDr. Nora Ku M.D.MD & VP of Clinical DevelopmentMore ExecutivesKey CompetitorsDyadic InternationalNASDAQ:DYAICellectar BiosciencesNASDAQ:CLRBBiora TherapeuticsNASDAQ:BIORLianBioNASDAQ:LIANRegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 30,205 shares on 3/11/2024Ownership: 2.398%Virtu Financial LLCBought 33,344 shares on 2/26/2024Ownership: 0.092%Vanguard Group Inc.Sold 30,205 shares on 2/15/2024Ownership: 2.398%Bridgeway Capital Management LLCBought 25,000 shares on 2/15/2024Ownership: 0.224%Barclays PLCBought 21,572 shares on 2/15/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions RAIN Stock Analysis - Frequently Asked Questions Should I buy or sell Rain Oncology stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares. View RAIN analyst ratings or view top-rated stocks. How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.06. What ETFs hold Rain Oncology's stock? ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO. Who are Rain Oncology's major shareholders? Rain Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.71%), Vanguard Group Inc. (2.40%), Vanguard Group Inc. (2.40%), Deltec Asset Management LLC (1.03%), Exchange Traded Concepts LLC (0.47%) and Northern Trust Corp (0.32%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology. View institutional ownership trends. This page (NASDAQ:RAIN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.